-
The UK’s opioid crisis: why the stats don’t add up
The Explainer A new report has revealed that the UK’s total of opioid-related deaths could be much greater than official figures show
The Explainer -
Human evolution may be responsible for autism rates
Under the radar Neurodiversity and a complex brain may go hand in hand
Under the radar -
Pregnancy in America
Feature Why is it getting riskier to give birth in the U.S.?
Feature -
RFK Jr.’s anti-vaccine crusade comes under fire
Feature Robert F. Kennedy Jr. faced a heated hearing as senators accused him of lying and spreading chaos
Feature -
Why social media is obsessed with cortisol
In The Spotlight Wellness trend is the latest response to an increasingly maligned hormone
In The Spotlight -
Fly like you know what you're doing with these 5 tips for healthy air travel
The Week Recommends Yes to stretching. Even more yesses to hydration.
The Week Recommends -
Why are Trump's health rumors about more than just presidential fitness?
TODAY'S BIG QUESTION Extended absences and unexplained bruises have raised concerns about both his well-being and his administration's transparency
TODAY'S BIG QUESTION -
Quit-smoking ads are being put out
Under the radar The dissolution of a government-funded campaign could lead to more smokers in the future
Under the radar -
An introvert's dream? Flu camps that offer £4,400 to spend two weeks alone
Under The Radar A fortnight in isolation may not be as blissful as it sounds
Under The Radar -
Scientists are speeding up evolution
Under the radar Proteins can evolve in minutes
Under the radar -
Sloth fever shows no signs of slowing down
The explainer The vector-borne illness is expanding its range
The explainer -
'With every technological advance, there are risks'
Instant Opinion Opinion, comment and editorials of the day
Instant Opinion -
'America is simply not investing at the level the crisis demands'
Instant Opinion Opinion, comment and editorials of the day
Instant Opinion -
The battle of the weight-loss drugs
Talking Point Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills
Talking Point
